136
Participants
Start Date
September 30, 2016
Primary Completion Date
September 30, 2020
Study Completion Date
June 30, 2022
CK-101
"Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily"
Research Site, Grafton
Research Site, Greenslopes
Research Site, Wellington
Research Site, Christchurch
Research Site, Pathumwan, Bangkok
Research Site, Ratchathewi District, Bangkok
Research Site, Bangkok Noi District, Bangkok
Research Site, Sarasota
Research Site, Nashville
Research Site, Khon Kaen
Research Site, Muang District, Chiang Mai
Research Site, St Louis
Research Site, Muang, Phitsanulok
Research Site, Hackensack
Research Site, Poznan
Research Site, Bydgoszcz
Research Site, Bydgoszcz
Research Site, Lublin
Research Site, Bialystok
Research Site, Szczecin
Lead Sponsor
Checkpoint Therapeutics, Inc.
INDUSTRY